- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01509560
PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Hessen
-
Wiesbaden, Hessen, Germany, 65191
- Zentrum für Knochenmark- und Blutstammzelltransplantation,
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients after allogeneic stem cell transplantation aged ≥ 18 years
- Prophylaxes of GvHD with calcineurin inhibitors (Ciclosporine A, Tacrolimus) and MTX or MMF (previous therapy of acute GvHD with additional prednisone is permitted)
- Increased risk of chronic GvHD, defined by
- Male with female donor
- HLA mismatch class I- or II towards GvHD
- Persistant active acute GvHD on day +50 after stem cell transplantation despite of high-dose steroids and cyclosporine
- Reduction of baseline FEV1 or DLCO (examined 0 - 50 days before transplantation) of ≥ 25%
- New occurrence of acute GvHD between day +50 and +100 after stem cell transplantation
- Informed concent
Exclusion Criteria:
- Use (prophylactic or therapeutic) of mTor inhibitors after SCT
- Overlap of acute and chronic GvHD
- Total cholesterol ≥ 3-fold of upper limit (UL) or triglycerides ≥ 3-fold UL
- GOT, GPT, Bilirubin ≥ 3-fold UL (if not related to GvHD)
- Creatinine ≥ 3-fold UL
- Confirmed active hepatitis B or C
- All circumstances where impaired wound healing might be a risk factor, esp. surgical interventions in the last weeks, ulcers of skin or mucosa
- Known intolerance to Everolimus, Sirolimus or other compoments of Certican®
- Lactose intolerance
- Pregnancy or lactation
- Women in reproductive age, except of women with the following criteria:
- Postmenopausal (12 month natural amenorrhea)
- Postoperativ (≥ 6 months after bilateral ovariectomy with / without hysterectomy)
- During therapy and at least 6 months after the last application of Everolimus: regular and correct high-effective contraception (Pearl-Index < 1; e. g. oral contraception, intrauterine device, implantate, contraceptive patch, combination of barrier methods (condom and cervical cap/diaphragm), abstinence
- Men, not using one of the following methods of contraception during therapy and at least 6 month after the last application of Everolimus:
- Sexual abstinence
- Vasectomy
- Condom
- Impairments or diseases reducing the ability of informed consent
- Participation of another study (e.g. for prophylactic immunsuppression in the stem cell transplantation procedure) within the last 60 day before recruitment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Everolimus
All patients will be given everolimus and the magnitude of the side effects will be measured
|
Start therapy: 2x 0.75 mg/day (morning and evening) to receive a serum trough level of 3 - 5 ng/ml. First evaluation of Everolimus serum level 3-7 days after start of therapy, second 7 days later, subsequently on study weeks 4, 6, 9, 12 and 16. Dose has to be adapted if trough level exceeds 5 ng/ml. As soon as Everolimus trough level exceeds 3 ng/ml after start of therapy, calineurine inhibitors (e.g. cyclosporine) will be reduced: halve of the dose for the 3 consecutive days, withdrawal on day 4. Prednisone will be reduced accordingly (a 22 weeks scheme is recommended) Everolimus will be used for 98 days or 14 weeks, as described above Everolimus therapy might be extended (independently of the study) if the patient suffering from milde chronic GvHD (according to NIH criteria) or milde PTOLD and lung function score is not reduced more than 25% since begin of Everolimus therapy Everolimus will be reduced to 50% of the dosage for 2 weeks before withdraw (normally weeks 15 and 16
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of early withdrawal of treatment within the first 6 weeks on Everolimus
Time Frame: 16 months
|
Primary endpoint Frequency of early withdrawal of treatment within the first 6 weeks on Everolimus Reasons for withdrawal of Everolimus treatment:
|
16 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse drug reactions on Everolimus
Time Frame: 16 months
|
|
16 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Michael Schleuning, Prof. Dr. med., Stiftung Deutsche Klinik für Diagnostik GmbH
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Ev02 (Everolimus-GvHD)
- 2010-023630-24 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Condition After Allogenic Peripheral Stem Cell Transplantation (SCT)
-
SanofiWithdrawnAllogenic Stem Cell Transplantation
-
Kyowa Kirin Co., Ltd.CompletedPeripheral Blood Stem Cell TransplantationJapan
-
University Hospital, LilleRecruitingAcute Leukemia | Aplasia | Hematopoietic Stem Cell Transplantation (SCT)France
-
Seoul National University HospitalCompletedQuality of Life After Stem Cell TransplantationKorea, Republic of
-
Chinese PLA General HospitalRecruitingPeripheral Blood Stem Cell TransplantationChina
-
National Institute of Mental Health (NIMH)CompletedCancer | Bone Marrow Transplantation | Allogeneic Peripheral Blood Stem Cell TransplantUnited States
-
Shanghai Jiao Tong University School of MedicineShanghai General Hospital, Shanghai Jiao Tong University School of MedicineUnknownPeripheral Blood Stem Cell Transplantation | aGVHDChina
-
University of FloridaUniversity of Florida HealthTerminatedMucositis | Stomatitis | Hematopoietic Stem Cell Transplantation | Peripheral Blood Stem Cell TransplantationUnited States
-
University of FloridaAmerican Cancer Society, Inc.CompletedHematopoietic Stem Cell Transplantation | Graft vs Host Disease | Graft Versus Host Disease | Peripheral Blood Stem Cell TransplantationUnited States
-
National Cancer Institute (NCI)RecruitingHematopoietic Stem Cell Transplantation | Peripheral Blood Stem Cell TransplantationUnited States
Clinical Trials on Everolimus
-
Novartis PharmaceuticalsTerminatedHepatocellular CarcinomaHong Kong, Taiwan, Thailand
-
German Breast GroupNovartisTerminatedMetastatic Breast CancerGermany
-
University of LuebeckTerminatedCoronary Artery DiseaseGermany
-
The Netherlands Cancer InstituteActive, not recruitingNeuroendocrine CarcinomasNetherlands
-
Novartis PharmaceuticalsCompletedLymphangioleiomyomatosis (LAM) | Tuberous Sclerosis Complex (TSC)United States, United Kingdom, Germany, Italy, Russian Federation, Netherlands, Japan, Canada, Poland, France, Spain
-
Guangdong Provincial People's HospitalNovartisUnknownNeuroendocrine Tumors | Carcinoid TumorChina
-
Novartis PharmaceuticalsTerminatedCarcinoma, Renal CellAustralia, Korea, Republic of
-
Centre Leon BerardSuspended
-
Novartis PharmaceuticalsCompletedGastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic SystemGermany
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed